{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:25:37Z","timestamp":1790688337746,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T00:00:00Z","timestamp":1666051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T00:00:00Z","timestamp":1666051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RR160027"],"award-info":[{"award-number":["RR160027"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01CA207445"],"award-info":[{"award-number":["R01CA207445"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["P50CA186784"],"award-info":[{"award-number":["P50CA186784"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Cancer Research UK and KWF Kankerbestrijding","award":["C38317\/A24043"],"award-info":[{"award-number":["C38317\/A24043"]}]},{"name":"The Kansas Institute for Precision Medicine \u2013 COBRE","award":["P20 GM130423"],"award-info":[{"award-number":["P20 GM130423"]}]},{"name":"NCATS Frontiers-CTSA","award":["UL1TR002366"],"award-info":[{"award-number":["UL1TR002366"]}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-21-1-0107"],"award-info":[{"award-number":["W81XWH-21-1-0107"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Ductal carcinoma in situ (DCIS) is the most common type of in situ premalignant breast cancers. What drives DCIS to invasive breast cancer is unclear. Basal-like invasive breast cancers are aggressive. We have previously shown that NRAS is highly expressed selectively in basal-like subtypes of invasive breast cancers and can promote their growth and progression. In this study, we investigated whether <jats:italic>NRAS<\/jats:italic> expression at the DCIS stage can control transition from luminal DCIS to basal-like invasive breast cancers.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Wilcoxon rank-sum test was performed to assess expression of <jats:italic>NRAS<\/jats:italic> in DCIS compared to invasive breast tumors in patients. <jats:italic>NRAS<\/jats:italic> mRNA\u00a0levels were also determined by fluorescence in situ hybridization in patient tumor microarrays (TMAs) with concurrent normal, DCIS, and invasive breast cancer, and association of <jats:italic>NRAS<\/jats:italic> mRNA levels with DCIS and invasive breast cancer was assessed by paired Wilcoxon signed-rank test. Pearson\u2019s correlation was calculated between <jats:italic>NRAS<\/jats:italic> mRNA levels and basal biomarkers in the TMAs, as well as in patient datasets. RNA-seq data were generated in cell lines, and unsupervised hierarchical clustering was performed after combining with RNA-seq data from a previously published patient cohort.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Invasive breast cancers showed higher <jats:italic>NRAS<\/jats:italic> mRNA levels compared to DCIS samples. These <jats:italic>NRAS<\/jats:italic><jats:sup><jats:italic>high<\/jats:italic><\/jats:sup> lesions were also enriched with basal-like features, such as basal gene expression signatures, lower ER, and higher p53 protein and Ki67 levels. We have shown previously that NRAS drives aggressive features in DCIS-like and basal-like SUM102PT cells. Here, we found that <jats:italic>NRAS<\/jats:italic>-silencing induced a shift to a luminal gene expression pattern. Conversely, <jats:italic>NRAS<\/jats:italic> overexpression in the luminal DCIS SUM225 cells induced a basal-like gene expression pattern, as well as an epithelial-to-mesenchymal transition signature. Furthermore, these cells formed disorganized mammospheres containing cell masses with an apparent reduction in adhesion.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>These data suggest that elevated  NRAS\u00a0levels in DCIS are not only a marker but can also control the emergence of basal-like features leading to more aggressive tumor activity, thus supporting the therapeutic hypothesis that targeting NRAS and\/or downstream pathways may block disease progression for a subset of DCIS patients with high <jats:italic>NRAS<\/jats:italic>.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13058-022-01565-5","type":"journal-article","created":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T11:04:10Z","timestamp":1666091050000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Elevated NRAS expression during DCIS is a potential driver for progression to basal-like properties and local invasiveness"],"prefix":"10.1186","volume":"24","author":[{"given":"Ze-Yi","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanan","family":"Elsarraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan T.","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenakshi","family":"Anurag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilda","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichao","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zifan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang H.-F.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ossama W.","family":"Tawfik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fariba","family":"Behbod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric C.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,18]]},"reference":[{"issue":"7","key":"1565_CR1","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1001\/jamaoncol.2015.2510","volume":"1","author":"SA Narod","year":"2015","unstructured":"Narod SA, Iqbal J, Giannakeas V, Sopik V, Sun P. Breast cancer mortality after a diagnosis of ductal carcinoma in situ. JAMA Oncol. 2015;1(7):888\u201396.","journal-title":"JAMA Oncol"},{"key":"1565_CR2","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.breast.2022.01.001","volume":"61","author":"AJ Maxwell","year":"2022","unstructured":"Maxwell AJ, Hilton B, Clements K, Dodwell D, Dulson-Cox J, Kearins O, Kirwan C, Litherland J, Mylvaganam S, Provenzano E, et al. Unresected screen-detected ductal carcinoma in situ: outcomes of 311 women in the forget-me-not 2 study. Breast. 2022;61:145\u201355.","journal-title":"Breast"},{"issue":"9","key":"1565_CR3","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1002\/cncr.20979","volume":"103","author":"LC Collins","year":"2005","unstructured":"Collins LC, Tamimi RM, Baer HJ, Connolly JL, Colditz GA, Schnitt SJ. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses\u2019 Health Study. Cancer. 2005;103(9):1778\u201384.","journal-title":"Cancer"},{"issue":"4","key":"1565_CR4","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/1097-0142(19820215)49:4<751::AID-CNCR2820490426>3.0.CO;2-Y","volume":"49","author":"DL Page","year":"1982","unstructured":"Page DL, Dupont WD, Rogers LW, Landenberger M. Intraductal carcinoma of the breast: follow-up after biopsy only. Cancer. 1982;49(4):751\u20138.","journal-title":"Cancer"},{"issue":"12","key":"1565_CR5","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1002\/cncr.21069","volume":"103","author":"ME Sanders","year":"2005","unstructured":"Sanders ME, Schuyler PA, Dupont WD, Page DL. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer. 2005;103(12):2481\u20134.","journal-title":"Cancer"},{"issue":"4","key":"1565_CR6","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.ejso.2017.12.007","volume":"44","author":"AJ Maxwell","year":"2018","unstructured":"Maxwell AJ, Clements K, Hilton B, Dodwell DJ, Evans A, Kearins O, Pinder SE, Thomas J, Wallis MG, Thompson AM, et al. Risk factors for the development of invasive cancer in unresected ductal carcinoma in situ. Eur J Surg Oncol. 2018;44(4):429\u201335.","journal-title":"Eur J Surg Oncol"},{"issue":"6178","key":"1565_CR7","first-page":"1454","volume":"343","author":"E Marshall","year":"2014","unstructured":"Marshall E. Breast cancer. Dare to do less Science. 2014;343(6178):1454\u20136.","journal-title":"Dare to do less Science"},{"issue":"23","key":"1565_CR8","doi-asserted-by":"publisher","first-page":"6103","DOI":"10.3390\/cancers13236103","volume":"13","author":"F Warnberg","year":"2021","unstructured":"Warnberg F, Karlsson P, Holmberg E, Sandelin K, Whitworth PW, Savala J, Barry T, Leesman G, Linke SP, Shivers SC, et al. Prognostic risk assessment and prediction of radiotherapy benefit for women with ductal carcinoma in situ (DCIS) of the breast, in a randomized clinical trial (SweDCIS). Cancers. 2021;13(23):6103.","journal-title":"Cancers"},{"issue":"23","key":"1565_CR9","doi-asserted-by":"publisher","first-page":"5895","DOI":"10.1158\/1078-0432.CCR-18-0842","volume":"24","author":"T Bremer","year":"2018","unstructured":"Bremer T, Whitworth PW, Patel R, Savala J, Barry T, Lyle S, Leesman G, Linke SP, Jirstrom K, Zhou W, et al. A biological signature for breast ductal carcinoma in situ to predict radiotherapy benefit and assess recurrence risk. Clin Cancer Res. 2018;24(23):5895\u2013901.","journal-title":"Clin Cancer Res"},{"issue":"19","key":"1565_CR10","doi-asserted-by":"publisher","first-page":"10869","DOI":"10.1073\/pnas.191367098","volume":"98","author":"T Sorlie","year":"2001","unstructured":"Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869\u201374.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1565_CR11","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1186\/1471-2407-13-512","volume":"13","author":"W Zhou","year":"2013","unstructured":"Zhou W, Jirstrom K, Amini RM, Fjallskog ML, Sollie T, Lindman H, Sorlie T, Blomqvist C, Warnberg F. Molecular subtypes in ductal carcinoma in situ of the breast and their relation to prognosis: a population-based cohort study. BMC Cancer. 2013;13:512.","journal-title":"BMC Cancer"},{"issue":"9","key":"1565_CR12","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1200\/JCO.1996.14.9.2584","volume":"14","author":"T Kuukasjarvi","year":"1996","unstructured":"Kuukasjarvi T, Kononen J, Helin H, Holli K, Isola J. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol. 1996;14(9):2584\u20139.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1565_CR13","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/nrc3106","volume":"11","author":"Y Pylayeva-Gupta","year":"2011","unstructured":"Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer. 2011;11(11):761\u201374.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1565_CR14","doi-asserted-by":"publisher","first-page":"3476","DOI":"10.1038\/s41467-018-05914-x","volume":"9","author":"OL Griffith","year":"2018","unstructured":"Griffith OL, Spies NC, Anurag M, Griffith M, Luo J, Tu D, Yeo B, Kunisaki J, Miller CA, Krysiak K, et al. The prognostic effects of somatic mutations in ER-positive breast cancer. Nat Commun. 2018;9(1):3476.","journal-title":"Nat Commun"},{"issue":"3","key":"1565_CR15","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.celrep.2015.06.044","volume":"12","author":"ZY Zheng","year":"2015","unstructured":"Zheng ZY, Tian L, Bu W, Fan C, Gao X, Wang H, Liao YH, Li Y, Lewis MT, Edwards D, et al. Wild-type N-Ras, overexpressed in basal-like breast cancer, promotes tumor formation by inducing IL-8 secretion via JAK2 activation. Cell Rep. 2015;12(3):511\u201324.","journal-title":"Cell Rep"},{"issue":"2","key":"1565_CR16","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s10549-019-05474-8","volume":"179","author":"M Banys-Paluchowski","year":"2020","unstructured":"Banys-Paluchowski M, Milde-Langosch K, Fehm T, Witzel I, Oliveira-Ferrer L, Schmalfeldt B, Muller V. Clinical relevance of H-RAS, K-RAS, and N-RAS mRNA expression in primary breast cancer patients. Breast Cancer Res Treat. 2020;179(2):403\u201314.","journal-title":"Breast Cancer Res Treat"},{"key":"1565_CR17","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1186\/1471-2105-12-323","volume":"12","author":"B Li","year":"2011","unstructured":"Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics. 2011;12:323.","journal-title":"BMC Bioinformatics"},{"issue":"4","key":"1565_CR18","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.1923","volume":"9","author":"B Langmead","year":"2012","unstructured":"Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012;9(4):357\u20139.","journal-title":"Nat Methods"},{"issue":"5","key":"1565_CR19","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.cell.2020.10.036","volume":"183","author":"K Krug","year":"2020","unstructured":"Krug K, Jaehnig EJ, Satpathy S, Blumenberg L, Karpova A, Anurag M, Miles G, Mertins P, Geffen Y, Tang LC, et al. Proteogenomic landscape of breast cancer tumorigenesis and targeted therapy. Cell. 2020;183(5):1436-1456 e1431.","journal-title":"Cell"},{"issue":"7","key":"1565_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7): e47.","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"1565_CR21","doi-asserted-by":"publisher","first-page":"Iqaa078","DOI":"10.1093\/nargab\/lqaa078","volume":"2","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Parmigiani G, Johnson WE. ComBat-seq: batch effect adjustment for RNA-seq count data. NAR Genom Bioinf. 2020;2(3):Iqaa078.","journal-title":"NAR Genom Bioinf"},{"issue":"18","key":"1565_CR22","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","volume":"32","author":"Z Gu","year":"2016","unstructured":"Gu Z, Eils R, Schlesner M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics. 2016;32(18):2847\u20139.","journal-title":"Bioinformatics"},{"issue":"4","key":"1565_CR23","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1016\/j.celrep.2016.06.051","volume":"16","author":"R Lesurf","year":"2016","unstructured":"Lesurf R, Aure MR, Mork HH, Vitelli V, Oslo Breast Cancer Research C, Lundgren S, Borresen-Dale AL, Kristensen V, Warnberg F, Hallett M, et al. Molecular features of subtype-specific progression from ductal carcinoma in situ to invasive breast cancer. Cell reports. 2016;16(4):1166\u201379.","journal-title":"Cell reports"},{"issue":"498","key":"1565_CR24","doi-asserted-by":"publisher","first-page":"eaao3332","DOI":"10.1126\/scisignal.aao3332","volume":"10","author":"AM Waters","year":"2017","unstructured":"Waters AM, Ozkan-Dagliyan I, Vaseva AV, Fer N, Strathern LA, Hobbs GA, Tessier-Cloutier B, Gillette WK, Bagni R, Whiteley GR, et al. Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies. Sci Signal. 2017;10(498):eaao3332.","journal-title":"Sci Signal"},{"issue":"9","key":"1565_CR25","doi-asserted-by":"publisher","first-page":"3108","DOI":"10.1158\/0008-5472.CAN-07-5644","volume":"68","author":"M Smid","year":"2008","unstructured":"Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, Foekens JA, Martens JW. Subtypes of breast cancer show preferential site of relapse. Cancer Res. 2008;68(9):3108\u201314.","journal-title":"Cancer Res"},{"issue":"6797","key":"1565_CR26","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747\u201352.","journal-title":"Nature"},{"issue":"3","key":"1565_CR27","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s10549-011-1894-3","volume":"133","author":"ES Knudsen","year":"2012","unstructured":"Knudsen ES, Ertel A, Davicioni E, Kline J, Schwartz GF, Witkiewicz AK. Progression of ductal carcinoma in situ to invasive breast cancer is associated with gene expression programs of EMT and myoepithelia. Breast Cancer Res Treat. 2012;133(3):1009\u201324.","journal-title":"Breast Cancer Res Treat"},{"issue":"18","key":"1565_CR28","doi-asserted-by":"publisher","first-page":"3980","DOI":"10.1158\/0008-5472.CAN-15-0506","volume":"75","author":"MC Abba","year":"2015","unstructured":"Abba MC, Gong T, Lu Y, Lee J, Zhong Y, Lacunza E, Butti M, Takata Y, Gaddis S, Shen J, et al. A molecular portrait of high-grade ductal carcinoma in situ. Cancer Res. 2015;75(18):3980\u201390.","journal-title":"Cancer Res"},{"issue":"5","key":"1565_CR29","doi-asserted-by":"publisher","first-page":"R97","DOI":"10.1186\/bcr3035","volume":"13","author":"A Rody","year":"2011","unstructured":"Rody A, Karn T, Liedtke C, Pusztai L, Ruckhaeberle E, Hanker L, Gaetje R, Solbach C, Ahr A, Metzler D, et al. A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res BCR. 2011;13(5):R97.","journal-title":"Breast Cancer Res BCR"},{"issue":"7403","key":"1565_CR30","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/nature10933","volume":"486","author":"SP Shah","year":"2012","unstructured":"Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012;486(7403):395\u20139.","journal-title":"Nature"},{"issue":"7","key":"1565_CR31","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1093\/jmcb\/mjz067","volume":"11","author":"J Bargonetti","year":"2019","unstructured":"Bargonetti J, Prives C. Gain-of-function mutant p53: history and speculation. J Mol Cell Biol. 2019;11(7):605\u20139.","journal-title":"J Mol Cell Biol"},{"issue":"23","key":"1565_CR32","doi-asserted-by":"publisher","first-page":"9148","DOI":"10.1158\/0008-5472.CAN-09-1043","volume":"69","author":"C Jedeszko","year":"2009","unstructured":"Jedeszko C, Victor BC, Podgorski I, Sloane BF. Fibroblast hepatocyte growth factor promotes invasion of human mammary ductal carcinoma in situ. Can Res. 2009;69(23):9148\u201355.","journal-title":"Can Res"},{"issue":"7","key":"1565_CR33","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1158\/0008-5472.CAN-06-4065","volume":"67","author":"G Huper","year":"2007","unstructured":"Huper G, Marks JR. Isogenic normal basal and luminal mammary epithelial isolated by a novel method show a differential response to ionizing radiation. Cancer Res. 2007;67(7):2990\u20133001.","journal-title":"Cancer Res"},{"issue":"6","key":"1565_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0064388","volume":"8","author":"CE Smart","year":"2013","unstructured":"Smart CE, Morrison BJ, Saunus JM, Vargas AC, Keith P, Reid L, Wockner L, Askarian-Amiri M, Sarkar D, Simpson PT, et al. In vitro analysis of breast cancer cell line tumourspheres and primary human breast epithelia mammospheres demonstrates inter- and intrasphere heterogeneity. PLoS One. 2013;8(6): e64388.","journal-title":"PLoS One"},{"issue":"3","key":"1565_CR35","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.scr.2013.01.007","volume":"10","author":"Q Dong","year":"2013","unstructured":"Dong Q, Wang D, Bandyopadhyay A, Gao H, Gorena KM, Hildreth K, Rebel VI, Walter CA, Huang C, Sun LZ. Mammospheres from murine mammary stem cell-enriched basal cells: clonal characteristics and repopulating potential. Stem Cell Res. 2013;10(3):396\u2013404.","journal-title":"Stem Cell Res"},{"issue":"12","key":"1565_CR36","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1016\/S0959-8049(01)00165-4","volume":"37","author":"A Ringberg","year":"2001","unstructured":"Ringberg A, Anagnostaki L, Anderson H, Idvall I, Ferno M. South Sweden breast cancer G: Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics. Eur J Cancer. 2001;37(12):1514\u201322.","journal-title":"Eur J Cancer"},{"issue":"2","key":"1565_CR37","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s10549-016-3814-z","volume":"157","author":"AM Molinaro","year":"2016","unstructured":"Molinaro AM, Sison JD, Ljung BM, Tlsty TD, Kerlikowske K. Risk prediction for local versus regional\/metastatic tumors after initial ductal carcinoma in situ diagnosis treated by lumpectomy. Breast Cancer Res Treat. 2016;157(2):351\u201361.","journal-title":"Breast Cancer Res Treat"},{"key":"1565_CR38","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41523-020-0167-x","volume":"6","author":"H Bergholtz","year":"2020","unstructured":"Bergholtz H, Lien TG, Swanson DM, Frigessi A. Oslo breast cancer research C, daidone MG, tost J, warnberg F, sorlie T: contrasting DCIS and invasive breast cancer by subtype suggests basal-like DCIS as distinct lesions. NPJ Breast Cancer. 2020;6:26.","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"1565_CR39","doi-asserted-by":"publisher","first-page":"16932","DOI":"10.1038\/s41598-018-35237-2","volume":"8","author":"ZY Zheng","year":"2018","unstructured":"Zheng ZY, Li J, Li F, Zhu Y, Cui K, Wong ST, Chang EC, Liao YH. Induction of N-Ras degradation by flunarizine-mediated autophagy. Sci Rep. 2018;8(1):16932.","journal-title":"Sci Rep"},{"issue":"2","key":"1565_CR40","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s10549-021-06367-5","volume":"190","author":"LJ Goldstein","year":"2021","unstructured":"Goldstein LJ, Mansutti M, Levy C, Chang JC, Henry S, Fernandez-Perez I, Prausova J, Staroslawska E, Viale G, Butler B, et al. A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida). Breast Cancer Res Treat. 2021;190(2):265\u201375.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"1565_CR41","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1074\/mcp.TIR118.000943","volume":"18","author":"K Krug","year":"2019","unstructured":"Krug K, Mertins P, Zhang B, Hornbeck P, Raju R, Ahmad R, Szucs M, Mundt F, Forestier D, Jane-Valbuena J, et al. A curated resource for phosphosite-specific signature analysis. Mol Cell Proteomics. 2019;18(3):576\u201393.","journal-title":"Mol Cell Proteomics"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-022-01565-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-022-01565-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-022-01565-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T13:09:51Z","timestamp":1666098591000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-022-01565-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,18]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1565"],"URL":"https:\/\/doi.org\/10.1186\/s13058-022-01565-5","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,18]]},"assertion":[{"value":"7 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patients gave written informed consent for participation in this University of Kansas Medical Center Institutional Review Board approved study, which allowed collection of de-identified surgical tissue for research. The rest of the gene expression patient datasets are already published and publicly available.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Our study does not contain any individual data, and all authors have approved the contents in this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declared no conflict or personal or financial interests, except BZ who received personal fees from AstraZeneca and TNIK PHARMACEUTICALS LTD outside the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"68"}}